Welcome to the MOSES (Morbidity and mortality after Stroke – Eprosartan vs nitrendipine for Secondary prevention) study website. These pages provide information about the MOSES study, as well as important facts about stroke and stroke prevention.
The manuscript entitled "Morbidity and Mortality after Stroke - Eprosartan Compared to Nitrendipine for Secondary Prevention. Principal Results of a Prospective Randomised Controlled Study" by J Schrader et al. for the MOSES Study Group has been published in Stroke 2005; 36: 1218-1224.
Editorial Comment: Secondary Prevention of Stroke Is Important: But All Hypertensive Drugs Are Not Created Equal? Timo E. Strandberg
TEVETEN® (eprosartan) reduces future risk in hypertensive stroke patients
The long-anticipated results of the MOSES study were presented to an audience of cardiologists and investigators during a satellite symposium held at the XXVI Congress of the European Society of Cardiology (ESC), 30 August 2004, Messe-München, Munich, Germany.
To view the symposium in audio and video with synchronized slide show, please visit www.prous.com/eprosartan
